Lilly’s obesity pill, orforglipron, gets FDA fast-track voucher

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00
Eli Lilly and Co. (IBJ photo)

Eli Lilly and Co. is preparing for a massive rollout of its highly anticipated weight-loss pill, orforglipron, after receiving fast-track regulatory review by the U.S. Food and Drug Administration.

Shares of Lilly were up about 5%, to around $970 each, in Monday morning trading.

Last week, the Lilly experimental medication received the FDA’s Commissioner’s National Priority Voucher, a pilot program for accelerated drug review for companies supporting national interests, according to the FDA.

Lilly previously said it plans to submit orforglipron to global regulatory authorities by the end of the year for the treatment of obesity. The company also said it plans to submit orforglipron for regulatory approval for the treatment of Type 2 diabetes in 2026.

The type of fast-track voucher granted to Lilly is for products for which the drugmaker has “agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need,” FDA Commissioner Dr. Marty Makary said in a written statement.

Under the program, priority voucher holders will receive a regulatory decision within months—a drastic reduction in the typical timeline for drug approval, according to the FDA.

Voucher comes after Trump admin deal

Lilly also announced last week a broader agreement with the U.S. government to expand access to obesity medications and reduce costs for patients on government insurance programs and those paying for the drugs out of pocket. The deal also reduces tariff burdens on the Indianapolis-based pharmaceutical giant.

Under the deal with the Trump administration, as early as April 1, those on Medicare will pay no more than $50 a month for Zepbound, another Lilly weight-loss drug available in a multi-dose pen, and for orforglipron, which, once approved by the FDA, will be a once-daily pill for obesity.

Patients not covered by Medicare who pay for their own obesity medications can use the LillyDirect self-pay pharmacy. Zepbound, for example, costs $299 per month for the lowest dose and $499 for other doses, a $50 discount from current prices.

In return, Lilly will receive three years of tariff relief and will not be subject to future pricing mandates, the company said in a Nov. 6 news release.

Lilly said the scope of the Trump administration agreement does not include pricing obligations in the commercial channel.

GLP-1 pill brings big opportunity

Wegovy, made by Novo Nordisk, also received FDA fast-track status for the treatment of obesity and related health conditions.

Lilly sees a massive opportunity in the oral GLP-1, in part because patients prefer swallowing pills to getting shots. The drug manufacturer’s current GLP-1 weight-loss medication, Zepbound, is administered through weekly injections.

“We’re interested in getting orforglipron to as many patients around the world as fast as we can, including those in the U.S.,” Lilly CEO David Ricks said during the company’s recent third-quarter earnings call with analysts. “I think investors can expect us to be pursuing an all the above strategy to get the medicine out more quickly.”

Lilly has also seen continued, significant growth in the weight-loss market. Sales of Mounjaro totaled $6.52 billion for the third quarter, up 109% from the same quarter a year ago. Zepbound revenue was $3.59 billion, up 185%.

Lilly is making plans to produce massive quantities of the pills. The company’s planned new $3 billion facility in the Netherlands, $6.5 billion facility in Texas, and $1.2 billion expanded facility in Puerto Rico will all produce orforglipron.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In